Local Recurrence Less Likely With Mastectomy in Younger Breast Cancer Patients

Article

Over the long term, local recurrence is more likely in young women with invasive breast cancer who undergo breast conserving surgery compared with those who undergo mastectomy, though survival is no different.

Over the long term, local recurrence is more likely in young women with invasive breast cancer who undergo breast conserving surgery (BCS) compared with those who undergo mastectomy, though survival is no different, according to a new study. Also, achieving clear surgical margins and the use of post-mastectomy chest wall radiotherapy (RT) was more important than extent of surgery for positive outcomes.

The two surgical options “have been looked at in randomized controlled trials, but they’ve always had very small numbers of young women,” said Tom Maishman, of the University of Southampton in the United Kingdom. He presented the study during a poster discussion session at the San Antonio Breast Cancer Symposium, held December 6–10.

The new study included 2,882 women included in the POSH trial, which involves only women aged 18 to 40 years. Approximately half underwent mastectomy (n = 1,464) and half underwent BCS (n = 1,395); mastectomy patients were more likely to have estrogen receptor– or progesterone receptor–positive disease, and were more likely to be HER2-positive as well. Mastectomy patients were also more likely to have multifocal disease than BCS patients (46.5% vs 12.5%; P < .001).

At 18 months, the rate of local recurrence was similar between the two groups (1% vs 1%). At 5 years, though, the rates had separated, with a 5.33% rate of local recurrence in BCS patients and 2.63% in mastectomy patients, for a hazard ratio (HR) of 3.39 (95% CI, 2.03–5.66; P < .001). At 10 years they separated further, at 11.68% in BCS patients and 4.93% in mastectomy patients, for an HR of 5.27 (95% CI, 2.43–11.43; P < .001).

Distant metastases and mortality were better with BCS, but adjustment for prognostic factors eliminated this difference.

The use of chest wall RT in patients who underwent mastectomy yielded lower risk of local recurrence. At 10 years, those who underwent RT had a recurrence rate of 6.45%, compared with 4.06% in those who did not, for an HR of 0.46 (95% CI, 0.24–0.86; P = .015). In BCS patients positive surgical margins were associated with poorer rates of distant metastases and overall survival (P < .001).

“Achieving clear surgical margins and appropriate post-mastectomy chest wall RT appears more important than the extent of surgery for positive outcomes in young women with breast cancer,” Maishman concluded.

Ann Partridge, MD, MPH, of the Dana-Farber Cancer Institute in Boston, was the discussant for the session, and noted that an important question is that of heredity, meaning whether or not the local recurrences are actually new primary tumors.

“I think these data confirm what has now been incorporated into international guidelines, which is in young women we really need to pay attention to margins,” Partridge said. Also, she stressed that the growing body of radiation oncology literature suggest there is substantial benefit with RT in young patients.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.